Medical Properties Trust (MPW) Financials

$4.38 +0.07 (+1.62%)

Closing price 03:59 PM Eastern

Extended Trading

$4.37 -0.01 (-0.32%)

As of 07:46 PM Eastern

Annual Income Statements for Medical Properties Trust

This table shows Medical Properties Trust's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	140	225	290	1,017	375	431	656	903	-556	-2,410
Consolidated Net Income / (Loss)	140	226	291	1,018	376	432	657	904	-556	-2,408
Net Income / (Loss) Continuing Operations	140	226	291	1,018	376	432	657	904	-556	-2,408
Total Pre-Tax Income	140	219	294	1,019	374	463	731	960	-687	-2,364
Total Revenue	442	541	705	785	616	921	1,177	1,543	872	996
Net Interest Income / (Expense)	0.00	0.00	0.00	162	-238	-329	-367	0.00	0.00	0.00
Total Interest Income	0.00	0.00	0.00	162	0.00	0.00	0.00	0.00	0.00	0.00
Total Interest Expense	0.00	0.00	0.00	0.00	238	329	367	0.00	0.00	0.00
Total Non-Interest Income	442	541	705	622	854	1,249	1,545	1,543	872	996
Other Service Charges	112	108	129	-	150	142	169	166	69	49
Other Non-Interest Income	330	433	576	622	704	1,107	1,376	1,377	803	947
Total Non-Interest Expense	179	359	396	495	294	421	506	898	1,202	1,027
Net Occupancy & Equipment Expense	3.79	-	-	-	-	-	-	46	42	27
Other Operating Expenses	44	211	241	314	120	157	185	520	557	552
Depreciation Expense	70	94	125	133	152	264	321	333	603	448
Nonoperating Income / (Expense), net	-123	37	-15	729	51	-36	60	315	-357	-2,333
Income Tax Expense	-	-6.83	2.68	0.93	-2.62	31	74	56	-131	44
Net Income / (Loss) Attributable to Noncontrolling Interest	0.33	0.89	1.45	1.79	1.72	0.82	0.92	1.22	0.38	1.98
Basic Earnings per Share	$0.64	$0.86	$0.82	$2.77	$0.87	$0.81	$1.11	$1.50	($0.93)	($4.02)
Weighted Average Basic Shares Outstanding	218.00M	260.41M	349.90M	365.36M	427.08M	529.24M	588.82M	598.63M	598.52M	600.25M
Diluted Earnings per Share	$0.63	$0.86	$0.82	$2.76	$0.87	$0.81	$1.11	$1.50	($0.93)	($4.02)
Weighted Average Diluted Shares Outstanding	218.30M	261.07M	350.44M	366.27M	428.30M	530.46M	590.14M	598.84M	598.52M	600.25M
Weighted Average Basic & Diluted Shares Outstanding	218.10M	261.70M	353.40M	367M	520.93M	580M	599.90M	598.30M	599.10M	600.60M
Cash Dividends to Common per Share	$0.87	$0.90	$0.95	$0.99	$1.01	$1.07	$1.11	$1.15	$1.17	$0.38

This table shows Medical Properties Trust's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	222	-140	33	-42	117	-664	-876	-321	-801	-413
Consolidated Net Income / (Loss)	222	-140	33	-42	117	-664	-875	-320	-801	-412
Net Income / (Loss) Continuing Operations	222	-140	33	-42	117	-664	-875	-320	-801	-412
Total Pre-Tax Income	241	-125	37	-191	127	-660	-864	-305	-792	-403
Total Revenue	264	469	350	337	200	-16	271	165	120	440
Net Interest Income / (Expense)	-88	88	32	0.00	-107	75	11	-101	-106	197
Total Interest Income	0.00	-	32	0.00	0.00	-32	11	0.00	0.00	-11
Total Interest Expense	88	-88	0.00	0.00	107	-107	0.00	101	106	-208
Total Non-Interest Income	352	380	318	337	307	-90	260	267	226	243
Other Non-Interest Income	310	339	318	277	277	-69	260	250	216	220
Total Non-Interest Expense	127	312	230	529	122	320	222	145	246	412
Other Operating Expenses	46	185	146	165	45	201	147	43	42	320
Depreciation Expense	82	81	84	364	78	77	76	102	205	65
Nonoperating Income / (Expense), net	104	-286	-83	1.06	49	-324	-913	-325	-665	-430
Income Tax Expense	19	15	3.54	-148	10	3.98	11	15	9.03	9.56
Net Income / (Loss) Attributable to Noncontrolling Interest	0.23	0.26	0.24	-0.40	0.19	0.36	0.25	0.98	0.23	0.53
Basic Earnings per Share	$0.37	($0.24)	$0.05	($0.07)	$0.19	($1.10)	($1.46)	($0.54)	($1.34)	($0.68)
Weighted Average Basic Shares Outstanding	598.98M	598.63M	598.30M	598.34M	598.44M	598.52M	600.30M	600.06M	600.23M	600.25M
Diluted Earnings per Share	$0.37	($0.24)	$0.05	($0.07)	$0.19	($1.10)	($1.46)	($0.54)	($1.34)	($0.68)
Weighted Average Diluted Shares Outstanding	599.34M	598.84M	598.31M	598.34M	598.55M	598.52M	600.30M	600.06M	600.23M	600.25M
Weighted Average Basic & Diluted Shares Outstanding	598M	598.30M	598.30M	598.40M	599M	599.10M	600.10M	600.20M	600.40M	600.60M

This table details how cash moves in and out of Medical Properties Trust's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	62	-110	70	667	652	-928	-99	-207	3.02	84
Net Cash From Operating Activities	207	264	362	449	494	618	812	739	506	245
Net Cash From Continuing Operating Activities	207	264	362	449	499	618	812	739	506	245
Net Income / (Loss) Continuing Operations	140	226	291	1,018	376	432	657	904	-556	-2,408
Consolidated Net Income / (Loss)	140	226	291	1,018	376	432	657	904	-556	-2,408
Depreciation Expense	72	98	132	141	157	276	334	346	616	454
Amortization Expense	6.09	7.61	6.52	7.36	8.88	13	17	17	16	17
Non-Cash Adjustments to Reconcile Net Income	-26	-76	-44	906	-95	-101	-209	-441	555	2,198
Changes in Operating Assets and Liabilities, net	15	9.13	-24	-34	53	-2.60	13	-87	-125	-16
Net Cash From Investing Activities	-1,946	-927	-2,362	564	-4,884	-2,947	-3,858	396	518	1,318
Net Cash From Continuing Investing Activities	-1,946	-927	-2,362	564	-4,884	-2,947	-3,858	396	518	1,318
Purchase of Property, Leasehold Improvements and Equipment	-146	-171	-74	-	-84	-68	-68	-109	-114	-80
Purchase of Investment Securities	-2,590	-1,911	-2,361	-	-4,913	-4,348	-5,698	-1,748	-780	-682
Sale and/or Maturity of Investments	791	1,156	73	4,181	113	1,470	1,908	2,253	1,412	2,080
Net Cash From Financing Activities	1,801	553	2,070	-346	5,042	1,401	2,948	-1,343	-1,020	-1,479
Net Cash From Continuing Financing Activities	1,801	553	2,070	-252	5,042	1,812	2,948	-1,343	-1,020	-1,479
Net Change in Deposits	-11	15	28	21	-12	22	18	-5.02	10	2.24
Issuance of Debt	1,190	1,000	2,906	760	2,983	2,379	3,968	129	568	804
Issuance of Common Equity	817	1,174	548	188	2,533	411	1,051	0.00	0.00	0.00
Repayment of Debt	-0.28	-1,385	-1,038	-812	0.00	-800	-1,391	-666	-988	-1,833
Repurchase of Common Equity	-	-	-	-	-	0.00	0.00	-18	0.00	0.00
Payment of Dividends	-183	-218	-327	364	-412	-568	-643	-699	-615	-321
Other Financing Activities, Net	-13	-32	-46	-3.61	-50	369	-54	-84	5.18	-132
Cash Interest Paid	214	278	150	222	211	310	326	354	406	420

This table details how cash moves in and out of Medical Properties Trust's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Change in Cash & Equivalents	57	-80	64	6.53	30	-97	-23	384	-345	69
Net Cash From Operating Activities	214	181	136	77	158	135	74	35	59	77
Net Cash From Continuing Operating Activities	214	181	136	77	158	135	74	35	59	77
Net Income / (Loss) Continuing Operations	222	-140	33	-42	117	-664	-875	-320	-801	-412
Consolidated Net Income / (Loss)	222	-140	33	-42	117	-664	-875	-320	-801	-412
Depreciation Expense	85	85	88	368	81	80	77	104	206	66
Amortization Expense	3.90	3.92	4.01	4.08	3.88	3.80	3.70	3.79	4.78	5.08
Non-Cash Adjustments to Reconcile Net Income	-100	251	29	-181	-20	727	881	308	623	386
Changes in Operating Assets and Liabilities, net	3.02	-18	-18	-72	-23	-12	-12	-61	26	32
Net Cash From Investing Activities	324	-462	17	392	-62	170	-119	1,202	144	92
Net Cash From Continuing Investing Activities	324	-462	17	392	-62	170	-119	1,202	144	92
Purchase of Property, Leasehold Improvements and Equipment	-6.62	-11	-13	-15	-52	-34	-30	-15	-18	-16
Purchase of Investment Securities	-83	-452	-192	-250	-232	-106	-222	-289	-186	16
Sale and/or Maturity of Investments	414	1.01	222	657	223	310	133	1,507	348	92
Net Cash From Financing Activities	-481	201	-89	-462	-67	-403	22	-854	-548	-100
Net Cash From Continuing Financing Activities	-481	201	-89	-462	-67	-403	22	-854	-548	-100
Net Change in Deposits	-5.77	-2.43	-2.69	9.85	0.60	2.39	6.23	2.28	-9.23	2.96
Repayment of Debt	-201	204	0.00	-215	-319	-454	0.00	-1,381	-401	-51
Payment of Dividends	-174	-174	-177	-174	-174	-91	-93	-90	-90	-48
Other Financing Activities, Net	-36	-0.63	-5.77	13	-0.72	-0.98	-2.57	-78	-48	-3.76
Cash Interest Paid	76	68	116	111	95	84	132	123	95	71

This table presents Medical Properties Trust's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Total Assets	5,609	6,419	9,020	8,844	14,467	16,829	20,520	19,658	18,305	14,295
Cash and Due from Banks	196	83	171	821	1,462	550	459	236	250	332
Loans and Leases, Net of Allowance	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Mortgage Servicing Rights	758	1,060	1,778	1,213	1,275	248	213	364	309	120
Other Assets	1,433	1,043	1,369	1,156	2,934	2,964	3,239	5,381	2,663	2,375
Total Liabilities & Shareholders' Equity	5,609	6,419	9,020	8,844	14,467	16,829	20,520	19,658	18,305	14,295
Total Liabilities	3,502	3,165	5,185	4,283	7,439	9,485	12,074	11,064	10,671	9,461
Long-Term Debt	3,323	2,909	4,899	4,037	7,024	8,865	11,283	10,268	10,064	8,848
Other Long-Term Liabilities	29	20	229	41	554	181	791	174	607	613
Total Equity & Noncontrolling Interests	2,107	3,253	3,835	4,561	7,028	7,344	8,446	8,594	7,634	4,834
Total Preferred & Common Equity	2,102	3,248	3,821	4,547	7,028	7,339	8,440	8,593	7,632	4,833
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	2,102	3,248	3,821	4,547	14,119	7,339	8,440	8,593	7,632	4,833
Common Stock	2,594	3,776	4,333	4,443	14,029	7,462	8,565	8,536	8,561	8,586
Retained Earnings	-419	-434	-486	163	83	-71	-88	116	-972	-3,659
Accumulated Other Comprehensive Income / (Loss)	-73	-93	-26	-58	-63	-51	-37	-59	43	-94
Noncontrolling Interest	5.00	4.85	15	14	0.11	5.33	5.48	1.57	2.27	1.05

This table presents Medical Properties Trust's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024
Total Assets	19,043	19,650	19,204	19,005	17,301	16,195	15,236
Cash and Due from Banks	299	302	324	340	224	607	276
Loans and Leases, Net of Allowance	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Premises and Equipment, Net	-	11,885	-	-	-	11,949	11,654
Mortgage Servicing Rights	306	346	299	302	310	399	298
Intangible Assets	11,994	-	11,882	11,727	11,401	-1,418	-1,424
Other Assets	6,444	3,418	6,699	6,635	5,366	4,658	4,432
Total Liabilities & Shareholders' Equity	19,043	19,650	19,204	19,005	17,301	16,195	15,236
Total Liabilities	10,210	11,207	10,890	10,719	10,597	10,002	9,795
Other Short-Term Payables	569	-	445	376	303	447	418
Long-Term Debt	9,476	10,438	10,238	10,157	10,099	9,369	9,216
Other Long-Term Liabilities	165	769	207	186	195	186	161
Total Equity & Noncontrolling Interests	8,833	8,443	8,315	8,285	6,704	6,193	5,441
Total Preferred & Common Equity	8,832	8,442	8,314	8,285	6,702	6,190	5,439
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	8,832	8,442	8,314	8,285	6,702	6,190	5,439
Common Stock	8,538	8,542	8,548	8,559	8,568	8,572	8,579
Retained Earnings	433	-25	-241	-215	-1,847	-2,348	-3,198
Accumulated Other Comprehensive Income / (Loss)	-139	-75	6.68	-60	-19	-34	57
Noncontrolling Interest	1.47	1.57	0.90	0.89	2.27	2.90	2.54

This table displays calculated financial ratios and metrics derived from Medical Properties Trust's official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	41.39%	22.46%	30.23%	11.32%	-21.43%	49.34%	27.89%	31.05%	-43.49%	14.19%
EBITDA Growth	67.87%	-15.80%	55.66%	-1.87%	11.24%	61.61%	29.56%	-1.43%	-70.02%	45.73%
EBIT Growth	84.14%	-30.85%	69.54%	-6.06%	11.28%	54.89%	34.34%	-3.97%	-151.17%	90.61%
NOPAT Growth	84.14%	-28.69%	62.91%	-5.28%	12.16%	43.50%	29.42%	0.62%	-138.04%	90.61%
Net Income Growth	175.47%	61.47%	28.90%	249.71%	-63.04%	14.84%	51.97%	37.58%	-161.53%	-333.07%
EPS Growth	117.24%	36.51%	-4.65%	236.59%	-68.48%	-6.90%	37.04%	35.14%	-162.00%	-332.26%
Operating Cash Flow Growth	37.59%	27.46%	37.29%	23.98%	10.03%	25.00%	31.41%	-8.95%	-31.56%	-51.47%
Free Cash Flow Firm Growth	-148.49%	66.14%	-315.65%	118.77%	-1,306.17%	67.02%	-72.40%	150.51%	-36.59%	327.77%
Invested Capital Growth	52.66%	13.50%	41.72%	-1.55%	63.43%	15.35%	21.71%	-4.39%	-6.17%	-22.69%
Revenue Q/Q Growth	-16.50%	42.10%	7.91%	-3.01%	-30.94%	12.28%	12.52%	27.47%	-35.71%	84.24%
EBITDA Q/Q Growth	-20.00%	-19.11%	69.77%	-12.92%	-0.49%	28.43%	4.48%	-3.10%	-62.20%	389.35%
EBIT Q/Q Growth	-25.82%	-29.21%	128.39%	-17.61%	-4.07%	40.56%	4.65%	-4.25%	-303.67%	92.13%
NOPAT Q/Q Growth	-25.82%	-27.00%	126.31%	-20.23%	-69.18%	40.19%	7.16%	-6.24%	-309.59%	92.12%
Net Income Q/Q Growth	11.69%	10.18%	11.11%	0.65%	-7.14%	14.80%	18.19%	-27.75%	-1,599.55%	9.45%
EPS Q/Q Growth	0.00%	4.88%	9.33%	0.73%	-13.86%	19.12%	15.63%	-28.23%	-1,228.57%	9.46%
Operating Cash Flow Q/Q Growth	10.76%	8.53%	14.81%	1.74%	3.51%	1.43%	7.80%	-6.70%	-8.28%	-19.31%
Free Cash Flow Firm Q/Q Growth	23.18%	-158.34%	39.41%	-16.01%	-105.26%	43.40%	1.93%	15.25%	4,172.58%	13.79%
Invested Capital Q/Q Growth	-0.86%	28.40%	0.70%	0.80%	16.29%	5.23%	4.16%	3.02%	-4.04%	-6.65%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
EBITDA Margin	77.20%	53.08%	63.45%	55.93%	79.19%	85.69%	86.80%	65.29%	34.64%	44.21%
EBIT Margin	59.57%	33.64%	43.79%	36.95%	52.34%	54.29%	57.02%	41.78%	-37.84%	-3.11%
Profit (Net Income) Margin	31.67%	41.75%	41.33%	129.82%	61.07%	46.96%	55.80%	58.58%	-63.79%	-241.91%
Tax Burden Percent	100.00%	103.12%	99.09%	99.91%	100.70%	93.30%	89.88%	94.18%	80.97%	101.87%
Interest Burden Percent	53.16%	120.36%	95.23%	351.62%	115.86%	92.72%	108.88%	148.88%	208.18%	7,631.82%
Effective Tax Rate	0.00%	-3.12%	0.91%	0.09%	-0.70%	6.70%	10.12%	5.82%	0.00%	0.00%
Return on Invested Capital (ROIC)	5.86%	3.24%	4.11%	3.34%	2.87%	3.08%	3.36%	3.15%	-1.26%	-0.14%
ROIC Less NNEP Spread (ROIC-NNEP)	1.37%	4.47%	3.73%	19.65%	3.80%	2.65%	3.89%	5.90%	-4.46%	-25.38%
Return on Net Nonoperating Assets (RNNOA)	2.16%	5.19%	4.11%	20.92%	3.63%	2.93%	4.96%	7.46%	-5.59%	-38.49%
Return on Equity (ROE)	8.02%	8.43%	8.22%	24.26%	6.50%	6.02%	8.32%	10.61%	-6.85%	-38.63%
Cash Return on Invested Capital (CROIC)	-35.83%	-9.40%	-30.42%	4.91%	-45.29%	-11.18%	-16.23%	7.63%	5.11%	25.46%
Operating Return on Assets (OROA)	5.64%	3.03%	4.00%	3.25%	2.77%	3.19%	3.59%	3.21%	-1.74%	-0.19%
Return on Assets (ROA)	3.00%	3.76%	3.77%	11.40%	3.23%	2.76%	3.52%	4.50%	-2.93%	-14.78%
Return on Common Equity (ROCE)	8.01%	8.41%	8.19%	24.18%	10.46%	8.98%	8.32%	10.60%	-6.85%	-38.62%
Return on Equity Simple (ROE_SIMPLE)	6.66%	6.96%	7.62%	22.40%	5.36%	5.89%	7.78%	10.52%	-7.29%	-49.83%
Net Operating Profit after Tax (NOPAT)	263	188	306	290	325	466	603	607	-231	-22
NOPAT Margin	59.57%	34.69%	43.39%	36.92%	52.71%	50.65%	51.25%	39.35%	-26.49%	-2.18%
Net Nonoperating Expense Percent (NNEP)	4.49%	-1.23%	0.37%	-16.31%	-0.93%	0.43%	-0.53%	-2.75%	3.20%	25.24%
SG&A Expenses to Revenue	0.86%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	2.96%	4.77%	2.74%
Operating Expenses to Revenue	40.43%	66.36%	56.21%	63.05%	47.66%	45.71%	42.98%	58.22%	137.84%	103.11%
Earnings before Interest and Taxes (EBIT)	263	182	309	290	323	500	671	645	-330	-31
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	341	287	447	439	488	789	1,022	1,007	302	440
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.70	0.69	0.81	0.85	0.54	1.17	1.29	0.63	0.35	0.49
Price to Tangible Book Value (P/TBV)	0.78	0.76	0.90	0.92	0.56	1.40	1.29	0.73	0.35	0.49
Price to Revenue (P/Rev)	3.31	4.17	4.38	4.93	12.33	9.32	9.26	3.49	3.07	2.38
Price to Earnings (P/E)	10.48	10.02	10.66	3.81	20.29	19.88	16.63	5.96	0.00	0.00
Dividend Yield	14.31%	12.93%	11.31%	9.43%	6.94%	6.75%	6.12%	12.90%	19.71%	11.65%
Earnings Yield	9.54%	9.98%	9.38%	26.27%	4.93%	5.03%	6.01%	16.78%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.85	0.83	0.90	0.83	0.94	1.04	1.10	0.82	0.71	0.80
Enterprise Value to Revenue (EV/Rev)	10.40	9.40	11.11	9.05	21.36	18.36	18.46	9.99	14.33	10.94
Enterprise Value to EBITDA (EV/EBITDA)	13.47	17.70	17.52	16.18	26.97	21.42	21.27	15.30	41.36	24.74
Enterprise Value to EBIT (EV/EBIT)	17.46	27.94	25.38	24.49	40.80	33.82	32.38	23.91	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	17.46	27.09	25.61	24.51	40.52	36.25	36.02	25.39	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	22.20	19.28	21.62	15.81	26.64	27.36	26.78	20.86	24.70	44.36
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	16.70	0.00	0.00	0.00	10.47	13.38	2.73
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	1.58	0.89	1.28	0.89	1.00	1.21	1.34	1.19	1.32	1.83
Long-Term Debt to Equity	1.58	0.89	1.28	0.89	1.00	1.21	1.34	1.19	1.32	1.83
Financial Leverage	1.58	1.16	1.10	1.06	0.95	1.11	1.28	1.26	1.25	1.52
Leverage Ratio	2.67	2.24	2.18	2.13	2.01	2.18	2.37	2.36	2.34	2.61
Compound Leverage Factor	1.42	2.70	2.07	7.48	2.33	2.02	2.58	3.51	4.87	199.55
Debt to Total Capital	61.19%	47.21%	56.09%	46.96%	49.98%	54.69%	57.19%	54.44%	56.87%	64.67%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	61.19%	47.21%	56.09%	46.96%	49.98%	54.69%	57.19%	54.44%	56.87%	64.67%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.09%	0.08%	0.17%	0.16%	0.00%	0.03%	0.03%	0.01%	0.01%	0.01%
Common Equity to Total Capital	38.72%	52.71%	43.75%	52.88%	100.48%	45.27%	42.78%	45.55%	43.12%	35.32%
Debt to EBITDA	9.74	10.13	10.96	9.20	14.39	11.24	11.04	10.19	33.32	20.10
Net Debt to EBITDA	9.17	9.84	10.57	7.33	11.39	10.54	10.59	9.96	32.50	19.35
Long-Term Debt to EBITDA	9.74	10.13	10.96	9.20	14.39	11.24	11.04	10.19	33.32	20.10
Debt to NOPAT	12.62	15.50	16.02	13.94	21.62	19.02	18.70	16.91	-43.58	-408.04
Net Debt to NOPAT	11.88	15.06	15.46	11.10	17.12	17.84	17.94	16.53	-42.50	-392.71
Long-Term Debt to NOPAT	12.62	15.50	16.02	13.94	21.62	19.02	18.70	16.91	-43.58	-408.04
Noncontrolling Interest Sharing Ratio	0.14%	0.18%	0.27%	0.34%	-61.07%	-49.30%	0.07%	0.04%	0.02%	0.03%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-1,610	-545	-2,265	425	-5,129	-1,691	-2,916	1,473	934	3,995
Operating Cash Flow to CapEx	141.42%	154.10%	490.75%	0.00%	589.65%	903.64%	1,198.46%	676.52%	442.02%	307.67%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	-21.56	-5.14	-7.94	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	2.08	1.88	2.21	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	1.73	1.67	2.02	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.09	0.09	0.09	0.09	0.05	0.06	0.06	0.08	0.05	0.06
Fixed Asset Turnover	0.18	0.16	0.15	0.16	0.10	0.10	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	5,430	6,163	8,734	8,598	14,052	16,209	19,728	18,863	17,698	13,682
Invested Capital Turnover	0.10	0.09	0.09	0.09	0.05	0.06	0.07	0.08	0.05	0.06
Increase / (Decrease) in Invested Capital	1,873	733	2,571	-136	5,454	2,157	3,519	-866	-1,165	-4,016
Enterprise Value (EV)	4,595	5,085	7,832	7,100	13,163	16,898	21,736	15,413	12,491	10,888
Market Capitalization	1,463	2,255	3,090	3,870	7,601	8,577	10,907	5,378	2,675	2,372
Book Value per Share	$8.84	$10.14	$10.49	$12.46	$27.29	$13.69	$14.15	$14.37	$12.74	$8.05
Tangible Book Value per Share	$7.86	$9.32	$9.41	$11.49	$26.21	$11.46	$14.15	$12.35	$12.74	$8.05
Total Capital	5,430	6,163	8,734	8,598	14,052	16,209	19,728	18,863	17,698	13,682
Total Debt	3,323	2,909	4,899	4,037	7,024	8,865	11,283	10,268	10,064	8,848
Total Long-Term Debt	3,323	2,909	4,899	4,037	7,024	8,865	11,283	10,268	10,064	8,848
Net Debt	3,127	2,826	4,727	3,217	5,561	8,316	10,824	10,033	9,814	8,516
Capital Expenditures (CapEx)	146	171	74	-54	84	68	68	109	114	80
Net Nonoperating Expense (NNE)	123	-38	15	-729	-52	34	-54	-297	325	2,387
Net Nonoperating Obligations (NNO)	3,323	2,909	4,899	4,037	7,024	8,865	11,283	10,268	10,064	8,848
Total Depreciation and Amortization (D&A)	78	105	139	149	165	289	351	363	632	471
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.64	$0.86	$0.82	$2.77	$0.87	$0.81	$1.11	$1.50	($0.93)	($4.02)
Adjusted Weighted Average Basic Shares Outstanding	218.00M	260.41M	349.90M	365.36M	427.08M	529.24M	588.82M	598.63M	598.52M	600.25M
Adjusted Diluted Earnings per Share	$0.63	$0.86	$0.82	$2.76	$0.87	$0.81	$1.11	$1.50	($0.93)	($4.02)
Adjusted Weighted Average Diluted Shares Outstanding	218.30M	261.07M	350.44M	366.27M	428.30M	530.46M	590.14M	598.84M	598.52M	600.25M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.87	$0.00	$1.11	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	237.85M	320.93M	364.69M	381.08M	520.93M	580M	599.90M	598.30M	599.10M	600.60M
Normalized Net Operating Profit after Tax (NOPAT)	227	165	335	338	241	466	603	607	-231	-22
Normalized NOPAT Margin	51.42%	30.47%	47.56%	43.03%	39.03%	50.65%	51.25%	39.35%	-26.49%	-2.18%
Pre Tax Income Margin	31.67%	40.49%	41.71%	129.94%	60.64%	50.33%	62.08%	62.20%	-78.78%	-237.48%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	1.36	1.52	1.83	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	1.37	1.42	1.64	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	1.00	1.31	1.64	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	1.01	1.21	1.46	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	130.77%	96.66%	112.19%	-35.73%	109.38%	131.39%	97.95%	77.29%	-110.66%	-13.33%
Augmented Payout Ratio	130.77%	96.66%	112.19%	-35.73%	109.38%	131.39%	97.95%	79.27%	-110.66%	-13.33%

This table displays calculated financial ratios and metrics derived from Medical Properties Trust's official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-10.92%	244.35%	-14.54%	-15.70%	-24.37%	-103.35%	-22.53%	-51.06%	-40.17%	2,904.12%
EBITDA Growth	-13.53%	-11.63%	-23.75%	-30.50%	-28.11%	-202.68%	-38.62%	-29.25%	-47.94%	139.10%
EBIT Growth	-18.46%	-15.46%	-34.60%	-214.03%	-43.37%	-314.50%	-59.22%	110.38%	-263.81%	108.09%
NOPAT Growth	-20.11%	-38.45%	-38.23%	-184.29%	-43.49%	-308.02%	-68.39%	110.38%	-224.54%	108.09%
Net Income Growth	29.54%	-167.79%	-94.77%	-122.33%	-47.35%	-373.27%	-2,750.25%	-653.33%	-785.17%	37.86%
EPS Growth	27.59%	-168.57%	-95.24%	-121.88%	-48.65%	-358.33%	-3,020.00%	-671.43%	-805.26%	38.18%
Operating Cash Flow Growth	0.79%	-22.66%	-24.38%	-53.51%	-26.04%	-25.22%	-45.19%	-53.93%	-62.58%	-43.37%
Free Cash Flow Firm Growth	122.40%	129.33%	135.59%	154.74%	-108.16%	-4.97%	699.61%	844.25%	6,084.82%	333.94%
Invested Capital Growth	-3.33%	-4.39%	-0.82%	-2.38%	0.73%	-6.17%	-11.01%	-16.12%	-20.53%	-22.69%
Revenue Q/Q Growth	-33.97%	77.31%	-25.26%	-3.66%	-40.76%	-107.84%	1,830.99%	-39.14%	-27.58%	267.54%
EBITDA Q/Q Growth	-13.13%	8.80%	-13.75%	-14.74%	-10.15%	-255.40%	151.56%	-1.73%	-33.88%	16.72%
EBIT Q/Q Growth	-18.65%	14.32%	-23.36%	-259.98%	140.40%	-533.01%	114.57%	-59.29%	-737.74%	121.40%
NOPAT Q/Q Growth	-20.72%	-10.58%	1.86%	-224.00%	153.14%	-429.19%	114.58%	-59.29%	-737.74%	121.40%
Net Income Q/Q Growth	16.81%	-163.15%	123.56%	-228.47%	375.48%	-667.68%	-31.92%	63.48%	-150.56%	48.52%
EPS Q/Q Growth	15.63%	-164.86%	120.83%	-240.00%	371.43%	-678.95%	-32.73%	63.01%	-148.15%	49.25%
Operating Cash Flow Q/Q Growth	29.93%	-15.34%	-25.10%	-43.58%	106.71%	-14.40%	-45.10%	-52.57%	67.89%	29.55%
Free Cash Flow Firm Q/Q Growth	230.18%	29.33%	-72.82%	20.42%	-119.42%	1,605.42%	127.13%	42.20%	23.06%	9.15%
Invested Capital Q/Q Growth	-3.66%	3.02%	0.10%	-1.74%	-0.59%	-4.04%	-5.06%	-7.39%	-5.82%	-6.65%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
EBITDA Margin	85.27%	52.33%	60.38%	53.44%	81.05%	0.00%	47.84%	77.24%	70.53%	22.40%
EBIT Margin	51.77%	33.38%	34.23%	-56.83%	38.76%	0.00%	18.02%	12.05%	-106.13%	6.18%
Profit (Net Income) Margin	84.01%	-29.92%	9.43%	-12.58%	58.49%	0.00%	-322.64%	-193.58%	-669.76%	-93.81%
Tax Burden Percent	92.28%	112.24%	90.31%	22.25%	92.08%	100.60%	101.27%	104.77%	101.14%	102.37%
Interest Burden Percent	175.87%	-79.88%	30.51%	99.45%	163.87%	196.62%	-1,768.51%	-1,533.18%	623.98%	-1,483.29%
Effective Tax Rate	7.72%	0.00%	9.69%	0.00%	7.92%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	3.10%	1.93%	2.42%	-3.01%	2.63%	0.00%	0.56%	0.31%	-2.43%	0.27%
ROIC Less NNEP Spread (ROIC-NNEP)	4.06%	-0.42%	1.69%	-2.11%	3.10%	0.00%	-8.30%	-3.10%	-9.78%	-4.29%
Return on Net Nonoperating Assets (RNNOA)	4.74%	-0.53%	2.00%	-2.50%	3.55%	0.00%	-11.25%	-4.18%	-13.80%	-6.50%
Return on Equity (ROE)	7.84%	1.39%	4.41%	-5.51%	6.19%	0.00%	-10.69%	-3.88%	-16.22%	-6.23%
Cash Return on Invested Capital (CROIC)	6.86%	7.63%	3.45%	3.22%	-0.12%	5.11%	10.08%	16.75%	21.21%	25.46%
Operating Return on Assets (OROA)	3.23%	2.56%	2.57%	-4.15%	2.76%	0.00%	0.77%	0.42%	-3.35%	0.38%
Return on Assets (ROA)	5.25%	-2.30%	0.71%	-0.92%	4.17%	0.00%	-13.85%	-6.79%	-21.14%	-5.73%
Return on Common Equity (ROCE)	7.84%	1.39%	6.68%	-5.51%	6.19%	0.00%	-10.69%	-3.88%	-16.22%	-6.23%
Return on Equity Simple (ROE_SIMPLE)	14.16%	0.00%	3.61%	0.87%	-0.40%	0.00%	-21.85%	-28.14%	-48.90%	0.00%
Net Operating Profit after Tax (NOPAT)	126	113	108	-134	71	-235	34	14	-89	19
NOPAT Margin	47.77%	24.09%	30.91%	-39.78%	35.69%	0.00%	12.61%	8.44%	-74.29%	4.32%
Net Nonoperating Expense Percent (NNEP)	-0.96%	2.35%	0.73%	-0.90%	-0.46%	4.22%	8.86%	3.40%	7.35%	4.56%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	48.23%	66.62%	65.77%	156.83%	61.24%	0.00%	81.98%	87.95%	206.13%	93.82%
Earnings before Interest and Taxes (EBIT)	137	156	120	-192	77	-335	49	20	-127	27
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	225	245	211	180	162	-252	130	128	84	98
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.66	0.63	0.50	0.60	0.35	0.35	0.40	0.42	0.65	0.49
Price to Tangible Book Value (P/TBV)	0.00	0.73	0.50	0.00	0.00	0.35	0.00	0.34	0.51	0.49
Price to Revenue (P/Rev)	4.80	3.49	2.87	3.49	2.17	3.07	3.35	4.17	6.50	2.38
Price to Earnings (P/E)	4.65	5.96	14.03	68.74	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	11.86%	12.90%	16.29%	14.01%	20.79%	19.71%	19.86%	13.92%	9.06%	11.65%
Earnings Yield	21.51%	16.78%	7.13%	1.45%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.82	0.82	0.76	0.80	0.69	0.71	0.75	0.73	0.85	0.80
Enterprise Value to Revenue (EV/Rev)	12.38	9.99	9.71	10.47	9.41	14.33	15.80	18.29	23.05	10.94
Enterprise Value to EBITDA (EV/EBITDA)	14.42	15.30	15.29	17.24	15.96	41.36	56.87	67.73	138.47	24.74
Enterprise Value to EBIT (EV/EBIT)	22.26	23.91	24.77	67.19	78.74	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	23.14	25.39	28.91	98.01	115.76	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	18.92	20.86	20.71	24.49	23.13	24.70	28.19	28.15	40.94	44.36
Enterprise Value to Free Cash Flow (EV/FCFF)	11.73	10.47	22.01	24.61	0.00	13.38	6.97	3.97	3.55	2.73
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	1.07	1.19	1.24	1.23	1.23	1.32	1.51	1.51	1.69	1.83
Long-Term Debt to Equity	1.07	1.19	1.24	1.23	1.23	1.32	1.51	1.51	1.69	1.83
Financial Leverage	1.17	1.26	1.18	1.19	1.15	1.25	1.36	1.35	1.41	1.52
Leverage Ratio	2.25	2.36	2.27	2.27	2.22	2.34	2.44	2.44	2.49	2.61
Compound Leverage Factor	3.96	-1.88	0.69	2.25	3.64	4.60	-43.14	-37.41	15.57	-38.78
Debt to Total Capital	51.76%	54.44%	55.28%	55.18%	55.07%	56.87%	60.10%	60.20%	62.88%	64.67%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	51.76%	54.44%	55.28%	55.18%	55.07%	56.87%	60.10%	60.20%	62.88%	64.67%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.01%	0.01%	0.01%	0.00%	0.00%	0.01%	0.01%	0.02%	0.02%	0.01%
Common Equity to Total Capital	48.24%	45.55%	44.71%	44.81%	44.92%	43.12%	39.89%	39.78%	37.11%	35.32%
Debt to EBITDA	9.12	10.19	11.09	11.87	12.71	33.32	45.83	55.90	102.47	20.10
Net Debt to EBITDA	8.83	9.96	10.77	11.50	12.29	32.50	44.81	52.28	99.40	19.35
Long-Term Debt to EBITDA	9.12	10.19	11.09	11.87	12.71	33.32	45.83	55.90	102.47	20.10
Debt to NOPAT	14.63	16.91	20.95	67.48	92.19	-43.58	-36.01	-70.84	-33.47	-408.04
Net Debt to NOPAT	14.17	16.53	20.35	65.35	89.10	-42.50	-35.21	-66.26	-32.47	-392.71
Long-Term Debt to NOPAT	14.63	16.91	20.95	67.48	92.19	-43.58	-36.01	-70.84	-33.47	-408.04
Noncontrolling Interest Sharing Ratio	0.04%	0.04%	-51.33%	0.04%	0.01%	0.00%	0.03%	0.03%	0.02%	0.03%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	757	979	264	318	-62	930	2,113	3,004	3,697	4,035
Operating Cash Flow to CapEx	3,233.06%	1,581.06%	1,020.52%	498.66%	303.81%	401.63%	248.76%	232.03%	320.77%	471.83%
Free Cash Flow to Firm to Interest Expense	8.59	0.00	0.00	0.00	-0.58	0.00	0.00	29.62	34.80	0.00
Operating Cash Flow to Interest Expense	2.43	0.00	0.00	0.00	1.48	0.00	0.00	0.35	0.56	0.00
Operating Cash Flow Less CapEx to Interest Expense	2.35	0.00	0.00	0.00	0.99	0.00	0.00	0.20	0.38	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.06	0.08	0.08	0.07	0.07	0.05	0.04	0.04	0.03	0.06
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	18,309	18,863	18,881	18,552	18,442	17,698	16,803	15,562	14,657	13,682
Invested Capital Turnover	0.07	0.08	0.08	0.08	0.07	0.05	0.04	0.04	0.03	0.06
Increase / (Decrease) in Invested Capital	-630	-866	-156	-452	133	-1,165	-2,078	-2,990	-3,786	-4,016
Enterprise Value (EV)	14,987	15,413	14,399	14,869	12,754	12,491	12,531	11,352	12,454	10,888
Market Capitalization	5,808	5,378	4,261	4,955	2,936	2,675	2,655	2,586	3,511	2,372
Book Value per Share	$14.74	$14.37	$14.11	$13.90	$13.84	$12.74	$11.19	$10.32	$9.06	$8.05
Tangible Book Value per Share	($5.28)	$12.35	$14.11	($5.96)	($5.75)	$12.74	($7.84)	$12.68	$11.43	$8.05
Total Capital	18,309	18,863	18,881	18,552	18,442	17,698	16,803	15,562	14,657	13,682
Total Debt	9,476	10,268	10,438	10,238	10,157	10,064	10,099	9,369	9,216	8,848
Total Long-Term Debt	9,476	10,268	10,438	10,238	10,157	10,064	10,099	9,369	9,216	8,848
Net Debt	9,177	10,033	10,136	9,914	9,817	9,814	9,874	8,763	8,940	8,516
Capital Expenditures (CapEx)	6.62	11	13	15	52	34	30	15	18	16
Net Nonoperating Expense (NNE)	-96	253	75	-92	-46	429	910	334	712	431
Net Nonoperating Obligations (NNO)	9,476	10,268	10,438	10,238	10,157	10,064	10,099	9,369	9,216	8,848
Total Depreciation and Amortization (D&A)	89	89	92	372	85	84	81	108	211	71
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.37	($0.24)	$0.05	($0.07)	$0.19	($1.10)	($1.46)	($0.54)	($1.34)	($0.68)
Adjusted Weighted Average Basic Shares Outstanding	598.98M	598.63M	598.30M	598.34M	598.44M	598.52M	600.30M	600.06M	600.23M	600.25M
Adjusted Diluted Earnings per Share	$0.37	($0.24)	$0.05	($0.07)	$0.19	($1.10)	($1.46)	($0.54)	($1.34)	($0.68)
Adjusted Weighted Average Diluted Shares Outstanding	599.34M	598.84M	598.31M	598.34M	598.55M	598.52M	600.30M	600.06M	600.23M	600.25M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	($0.07)	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	598M	598.30M	598.30M	598.40M	599M	599.10M	600.10M	600.20M	600.40M	600.60M
Normalized Net Operating Profit after Tax (NOPAT)	126	113	108	-134	71	-235	34	14	-89	19
Normalized NOPAT Margin	47.77%	24.09%	30.91%	-39.78%	35.69%	0.00%	12.61%	8.44%	-74.29%	4.32%
Pre Tax Income Margin	91.05%	-26.66%	10.44%	-56.52%	63.52%	0.00%	-318.61%	-184.76%	-662.21%	-91.64%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	1.55	0.00	0.00	0.00	0.73	0.00	0.00	0.20	-1.19	0.00
NOPAT to Interest Expense	1.43	0.00	0.00	0.00	0.67	0.00	0.00	0.14	-0.84	0.00
EBIT Less CapEx to Interest Expense	1.48	0.00	0.00	0.00	0.24	0.00	0.00	0.05	-1.37	0.00
NOPAT Less CapEx to Interest Expense	1.36	0.00	0.00	0.00	0.18	0.00	0.00	-0.01	-1.01	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	55.30%	77.29%	229.13%	964.46%	-2,133.72%	-110.66%	-36.30%	-25.70%	-13.69%	-13.33%
Augmented Payout Ratio	55.30%	79.27%	229.13%	964.46%	-2,133.72%	-110.66%	-36.30%	-25.70%	-13.69%	-13.33%

Key Financial Trends

Medical Properties Trust (NYSE: MPW) has exhibited substantial volatility in its financial performance over the last few years with a notable trend of net losses, especially through 2023 and into 2024, offset somewhat by positive cash flows from operating activities.

Key positive factors:

Consistent positive Net Cash From Continuing Operating Activities in recent quarters, with $76.7 million in Q4 2024 and $59.2 million in Q3 2024, demonstrating ongoing operational cash generation despite net losses.
Strong cash inflows from investing activities, highlighted by sales and maturities of investments generating $92.4 million in Q4 2024 and a notable $1.2 billion in Q2 2024, supporting investment liquidity.
Relatively stable common equity base, with total common equity around $5.4 billion in Q3 2024 and higher balances in earlier quarters, indicating a resilient capital foundation.
Moderate repayment of debt activities, such as $50.8 million in Q4 2024, reflecting some debt management efforts.
Good portfolio scale with premises and equipment net value exceeding $11.6 billion as of Q3 2024, which forms the core property base of the real estate investment trust.

Neutral considerations:

Earnings per share remain deeply negative through 2023 and 2024, with Q4 2024 diluted EPS at -$0.68, illustrating the magnitude of losses but no change in share count suggests no significant dilution.
Cash on hand and cash equivalents have fluctuated quarter to quarter but remain in the $200-$600 million range, suggesting reasonable liquidity though variable.
Consistent payment of dividends per share in most quarters, e.g., $0.08 in Q3 2024 and around $0.29 in several 2023 quarters, indicating a commitment to shareholder returns despite earnings challenges.

Negative factors:

Continued large net losses, including a Q4 2024 net loss of $412 million and similar multi-hundred million losses in previous quarters of 2023 and 2024.
Heavy nonoperating expenses impacting profitability, with Q4 2024 nonoperating loss at $430 million and sizable negative figures in prior quarters, greatly depressing total pre-tax income.
Significant depreciation and amortization expenses, e.g., nearly $65 million in Q4 2024 and over $200 million in Q3 2024, indicating large property asset write-downs or aging assets affecting net income.
Increasing long-term debt sustained near or above $9.2 billion in Q3 2024 from prior higher levels, raising concerns about leverage and interest burdens.
Negative retained earnings near -$3.2 billion in Q3 2024, highlighting accumulated losses eroding shareholder equity over time.
Negative trends in total revenue in some quarters, such as a negative $15.6 million in Q4 2023, suggest revenue recognition or operational difficulties.
Cash interest paid remains high (e.g., $70.7 million in Q4 2024) reflecting substantial interest expense weighing on financials.

Summary: Medical Properties Trust is facing challenging profitability with recurring net losses driven mainly by large nonoperating expenses and depreciation costs. However, the company’s ability to generate positive cash flow from operations and manage investing activities provides some offsetting strength. Persistent dividend payments and a substantial asset base support continued investor interest. The high leverage and negative retained earnings require careful monitoring, as they represent material risk factors. Investors should consider these dynamics and the company’s strategy to improve earnings and manage debt when evaluating MPW stock.

08/25/25 10:36 PMAI Generated. May Contain Errors.

Frequently Asked Questions About Medical Properties Trust's Financials

When does Medical Properties Trust's fiscal year end?

According to the most recent income statement we have on file, Medical Properties Trust's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Medical Properties Trust's net income changed over the last 9 years?

Medical Properties Trust's net income appears to be on a downward trend, with a most recent value of -$2.41 billion in 2024, falling from $139.93 million in 2015. The previous period was -$556.09 million in 2023. See Medical Properties Trust's forecast for analyst expectations on what’s next for the company.

How has Medical Properties Trust's revenue changed over the last 9 years?

Over the last 9 years, Medical Properties Trust's total revenue changed from $441.88 million in 2015 to $995.55 million in 2024, a change of 125.3%.

How much debt does Medical Properties Trust have?

Medical Properties Trust's total liabilities were at $9.46 billion at the end of 2024, a 11.3% decrease from 2023, and a 170.1% increase since 2015.

How much cash does Medical Properties Trust have?

In the past 9 years, Medical Properties Trust's cash and equivalents has ranged from $83.24 million in 2016 to $1.46 billion in 2019, and is currently $332.34 million as of their latest financial filing in 2024.

How has Medical Properties Trust's book value per share changed over the last 9 years?

Over the last 9 years, Medical Properties Trust's book value per share changed from 8.84 in 2015 to 8.05 in 2024, a change of -8.9%.

Related Companies

This page (NYSE:MPW) was last updated on 8/25/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Medical Properties Trust (MPW) Financials

Key Financial Trends

Frequently Asked Questions About Medical Properties Trust's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Medical Properties Trust (MPW) Financials

Annual Income Statements for Medical Properties Trust

Quarterly Income Statements for Medical Properties Trust

Annual Cash Flow Statements for Medical Properties Trust

Quarterly Cash Flow Statements for Medical Properties Trust

Annual Balance Sheets for Medical Properties Trust

Quarterly Balance Sheets for Medical Properties Trust

Annual Metrics And Ratios for Medical Properties Trust

Quarterly Metrics And Ratios for Medical Properties Trust

Key Financial Trends

Frequently Asked Questions About Medical Properties Trust's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools